Ivermectin and Doxycycline Combination as a Promising Drug Candidate
  Against SARS-CoV-2 Infection: A Computational Study by Rana, Meenakshi et al.
 
 
Ivermectin and Doxycycline Combination as a 
Promising Drug Candidate Against SARS-CoV-2 
Infection: A Computational Study 
 
Meenakshi Rana1, Pooja2, Papia Chowdhury2* 
 
1Department of Physics, School of Sciences, Uttarakhand Open University, 
 Haldwani, 263139, Uttarakhand, India 
 
2Department of Physics and Materials Science and Engineering, 
Jaypee Institute of Information Technology, Noida 201309, Uttar Pradesh, India. 
 
*Corresponding author: papia.chowdhury@jiit.ac.in 
 
Abstract 
In the present study, we have described how by using molecular docking and molecular dynamic (MD) 
simulation studies the combination drug of ivermectin and doxycycline can be used as a potential inhibitor 
for SARS-CoV-2 virus. In lieu of unavailability of specific cure of COVID-19 till now various 
possibilities for individual and combination drugs have been explored by the medical 
practitioners/scientists for the remedial purpose of CoV-2 infections. 3CLpro is the main protease of SARS-
CoV-2 virus which plays an essential role in mediating viral replication in the human body. 3CLpro protein 
can serve as an attractive drug target. In this work, we have studied drug: 3CLpro interactions by in silico 
molecular docking and MD simulation approaches. Common and easily available antiviral drugs 
ivermectin, doxycycline and their combination have been proved their valid candidature to be used as 









In the year 2020, the COVID-19 disease has spread globally and it has become an ongoing 
pandemic. Reported by the World Health Organization (WHO), due to this pandemic disease, more than 
35,659,007 numbers of active patients with 1,044,269 people have already died till 10 October 2020 
(https://covid19.who.int/). WHO declared the COVID-19 as a global health emergency. This disease is 
caused by a member of the coronavirus family [1]. Coronavirus was first found in 1930 in domestic poultry 
[2]. After that they were identified as causing several diseases in humans such as; respiratory illness, 
neurological, liver diseases, etc. [3]. Till now seven categories of this virus were identified. Among the 
seven categories of coronavirus, four causes only common cold with mild symptoms and in very rare cases 
pneumonia, respiratory infections in infants and older people [4]. The other three categories are Severe 
Acute Respiratory Syndrome Coronavirus (SARS-CoV) [5], Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) [6] and lastly the new one known as SARS-CoV-2 [7] identified in 2003, 2012 
and 2019 respectively. The international committee on taxonomy of viruses declared this new novel 
coronavirus as SARS-CoV-2 [8]. The SARS-CoV-2 is a single-stranded RNA virus and belongs to the 
Coronaviridae family having genome sequences of 79.5% sequence matching [9,10]. This shows that bats 
may be the carrier of this virus. The uniqueness of this virus is the presence of spike glycoproteins on its 
surface which gives a crown-like appearance of the virus structure. The crown-like spike protein surface 
of this virus can be easily visible with the help of electron microscopes. These spike proteins are a very 
significant part of SARS-CoV-2 [11] virus as they can easily interact with the human proteins which coats 
the inside of the nose and the cells of lungs. The interaction of spike protein and human protein causes 
change in spike protein of CoV-2 shape and causes the human receptor cell to swallow up the virus. 
Through the receptor binding domain (RBD), glycoproteins of the viruses start binding and entering to 
the host cells.  The key receptor for SARS-CoV-2 in humans is angiotensin converting enzyme 2 (ACE2) 
[12]. After entering the host cell, different human protease like airway trypsin-like protease (HAT), 
cathepsins and trans membrane protease serine 2 (TMPRSS2) divide the glycoproteins of the virus and so 
the conformational alteration of the virus structure occurs. From this phase the transformed virus replicates 
itself very fastly through some cyclic processes [12] and starts infecting the neighboring cells like lung, 
heart, brain cells and many others. From studies, scientists showed that the spike glycoproteins of 
coronavirus attach on the cell surface of the ACE2 receptor in the human body and allows the virus’s 
 
genetic material to enter the human cell [13]. Virus’s genetic material proceeds to hijack the metabolism 
of the cell and help the virus to divide. 
The main symptoms of this disease are fever, tiredness, dry cough. Other symptoms include 
shortness of breath, body pains, soreness in the throat and a small number of people reported diarrhea, 
running nose [14]. At the beginning these symptoms appear generally in mild form and gradually increase 
afterwards. The first infected patient by this virus was detected in Wuhan, China in December, 2019 
[15,16]. The highly contagious nature of this virus causes fast spreading of the diseases and became an 
ongoing pandemic virus spread globally. The spreading of virus occurs by the close contact along with 
the droplets spilled during talking, coughing and sneezing from the infected person [17]. Research works 
show that the chance of being infected by COVID-19 reduces by maintaining “social/physical” distancing 
along with proper hand-hygiene. Though there are many predictions about the airborne transmission of 
this disease, no scientifically valid evidence is available till now [18]. Depending upon the age and 
immunity of the person the symptoms likely to appear within two to fourteen days after infection with the 
virus [19]. Mortality increases with people aged over 60 years and having diseases such as hypertension, 
immune-weakening medications, diabetes, cardiovascular disease, chronic respiratory disease and cancer 
etc. Elderly people accounted for 42% of total fatalities and people with several diseases accounted for 
78% of total deaths [20]. However, very rare and mild with about 2.4% of the total reported cases have 
been reported in children (below age 19 years) [20]. 
To overcome this disease the whole world is in a race to find vaccines/drugs to attack this virus. 
Through clinical trials around 200 drugs and vaccines (approved by Food and Drug Administration). 
Covaxin, INO-4800, mRNA-1273, NVX-CoV2373, BBV152 etc. are some candidate vaccines that are 
currently under trials for COVID-19 [21]. Similarly examples of some FDA approved drugs for COVID-
19 are atazanavir, remdesivir, ritonavir, lopinavir, chloroquine, hydroxychloroquine (HCQ), cyclosporin, 
favipiravir etc. [22 -24]. Now according to most common treatment protocols since there is no detected 
and approved drug for COVID-19, patients with severe COVID-19 symptoms are usually treated by 
different purposed antiviral drugs as trial basis. Most of the above-mentioned drugs are usually antiviral 
in nature and are used for various viral diseases like: HIV medication, influenza, MERS and SARS 
diseases or for enhancing the immune system of human life [25-27]. Nowadays to identify potential drugs 
for various diseases, the concept of drug repurposing is widely used. Drug repurposing is an approach to 
find out the new uses for already available drugs that are originally developed for specific diseases [28]. 
Drug repurposing process has already proved to be very effective since many drugs have multiple protein 
 
targets and genetic factors; molecular pathways which can be shared by diverse diseases. For many years 
repurposing of drugs have been used such as favipiravir drug used for influenza virus, sofosbuvir drug 
used for hepatitis C virus have a strong repurposing prospective against Zika and Ebola [29], drugs 
oseltamivir, lopinavir, nelfinavir, atazanavir and ritonavir have been used for the treatment SARS and 
MERS [30,31]. But these drugs have their own toxicity related issues. On the other hand, some 
immunomodulatory plasma-based therapies are in use. Some food nutrients, herbal medicines having 
antiviral and immunity building properties are considered as an alternative of COVID-19 therapies 
[32,33]. In the same way, a repurposing of combination drugs with ribavirin, lopinavir, and ritonavir have 
already been anticipated for the COVID-19 patients [34]. Lopinavir and ritonavir combination are already 
in use for HIV treatment. However, till now no specific drugs and vaccines to combat against the COVID-
19 have been discovered. So there is an urgent and strong requirement for a newly invented 
drug/repurposed drug/combination drug to fight the disease. 
A combination drug includes two or more than two active ingredients mixed in a single dose form. 
For many years combination of drugs has been used for treating diseases such as 
aspirin/paracetamol/caffeine combination (Excedrin) is used for the treatment of headache and migraine 
[35], Carbidopa/levodopa/entacapone is used for the treatment of Parkinson's disease [36], and 
indacaterol/mometasone, used for the treatment of asthma [37]. Combination drug therapy is applied for 
many diseases such as: tuberculosis, leprosy, cancer, bacterial infections, malaria, and for many viral 
diseases like influenza, HIV/AIDS etc. [38]. Recently two combination drugs of 
Nitazoxanide/azithromycin [39] and another combination drug: lopinavir/oseltamivir/ritonavir are [40] 
being largely in use by medical practitioners to fight against SARS-CoV-2 infections. There are several 
advantages to the combination of drugs. They are increased action of drugs and efficiency, increase the 
efficiency of the therapeutic effect, reduced cost and side effects. However, combinations of drugs also 
include some disadvantages. Dose must be given in some fixed ratio otherwise mismatched 
pharmacokinetics may increase severe toxicity effects. Most important part of combination drugs is that 
repurposing of common available drugs may reduce cost, time of action and risk factor. Though several 
clinical trials are underway to identify drugs against SARS-CoV-2, but still currently there is availability 
of single approved drugs or vaccines. Urgent requirement of cure of current medical emergencies due to 
COVID-19 motivated us to investigate the possibility of inhibition of SARS-CoV-2 by using some 
repurposing of combination drugs: ivermectin and doxycycline. 
 
In the present paper, we have described how the combination drug of ivermectin and doxycycline, 
can be used as a potential SARS-CoV-2 Mpro inhibitor. For several years ivermectin (C48H72O14) is used 
to treat many infectious diseases in mammals. It is orally prescribed and has a low toxicity profile. 
Ivermectin has a broad-spectrum drug and possesses numerous effects on parasites, nematodes, 
arthropods, mycobacteria, flavivirus, and mammals [41]. By specifically targeting its NS3 helicase, it was 
also used to cure Japanese encephalitis virus (JEV) and yellow fever virus (YFV) [42,43]. In the late 
1970s, ivermectin was first known and in 1981 permitted for the use of animals [44]. Doxycycline is an 
antibiotic drug and used to treat the infections caused by bacteria. Doxycycline (C22H24N2O8) synthetically 
derived from oxytetracycline. This drug is a second-generation tetracycline, which is readily absorbed and 
bound to plasma proteins. It is mainly used for the treatment of pneumonia, respiratory tract infections, 
rocky mountain spotted fever, typhus fever and the typhus group, rickettsialpox, tick fevers, and urinary 
tract infections etc. It is also used to prevent malaria. Normally in the market it comes as a capsule, tablet, 
and suspension (liquid) to take orally. We have performed molecular docking and molecular dynamics 
(MD) simulations to understand the interaction mechanism of the proposed drugs for COVID-19.We hope 
that this work will provide other researchers with an important investigation way to identify new COVID-
19 treatment. 
 
2. Materials and Methods: 
2.1. Protein structure preparation 
Coronavirus possesses a number of polyproteins (structural and nonstructural). Among them 
3CLpro is a key CoV enzyme which plays an important role in mediating viral replication and transcription 
with the help of its glycoprotein. To rapidly discover the targeted drugs for clinical use, researchers 
focused on identifying drug leads that target 3CLpro protein of SARS-CoV-2 as it plays an important role 
for viral replication and transcription. In the present work, we have used one of 3CLpro proteases of CoV-
2 virus in a complex with an inhibitor N3 (PDBID: 6LU7) [45,46] as the target protein. 6LU7 can be 
proved to be an attractive target for designing effective drugs for COVID-19. We have chosen 6LU7 
protein for checking the inhibiting and binding properties of it with the ivermectin and doxycycline drugs. 
The structure of SARS-CoV-2 protease (6LU7.pdb) was used as a receptor and retrieved from Protein 
Data Bank (http://www.rcsb.org/) [45,47] and are shown in Figure 1 (a). We have removed water and 
hydrogen from it. All the existing properties of the proteins are described in Table 1. For the preparation 
 
of protein, we have used Auto Dock and MG Tools of AutoDock Vina software [48]. At first existing lead 
components, water molecules and ions have been removed from it. Later the process of cleaning has been 
done. We have calculated the Gasteiger charges of protein structures and after that polar hydrogen have 
been introduced. Then the non-polar bonds were merged and rotatable bonds were defined. Finally, by 
using Discovery studio 2020 [49] the intrinsic ligands were detached from the protein molecules and the 
final protein molecule was saved in the PDB format (Figure 2 a). 
Figure 1. a) Structure of receptor protein (6LU7). b) Structure of ivermectin c) Structure of doxycycline 
(from Protein data bank and Gauss view). In the figure red color: oxygen atom, blue: nitrogen atom, gray 
colour: carbon atom. 
 
For target protein by visualizing the dihedral angles ψ against φ of amino acid residues, Ramachandran 
plots have been drawn (Figure 2b). It predicted permissible and disfavored values of ψ and φ. 
Ramachandran plots for 6LU7 have been shown in the figure 2b, plot specifies localization on the chain 




Figure 2. a) Target variable viral proteins (6LU7) SARS-CoV-2 protease enzyme as receptor and b) 
Ramachandran plot for the receptor protein. 
 
 
2.3. Ligand drug molecules preparations 
Structures of drug molecules were drawn by using the Gaussian 09 program [50]. All the drugs 
optimization of geometries were carried out with Hartree fock and STO 3G basis set. Gauss View 5 
molecular visualization program was used for visualizing the optimized structure [51]. Open Babel 
software has been used to prepare 3D coordinates. ADME-T properties of molecules were identified using 
Organic chemistry portal (http://www.organic-chemistry.org/prog), a web based application for predicting 
in-silico ADME-T property. Protein–ligand interactive visualization and analysis was carried out in 
AutoDock 4.2 software on Windows 7 (64-bit). 
For the present work, we have selected two potential ligand drugs: ivermectin (C48H72O14) and 
doxycycline (C22H24N2O8). Detail structures of these molecules were downloaded from Drug Bank in pdb 
format (Figure 1 and Table 1).  Different chemical, physical, drug likeness and pharmacokinetics 
properties obtained from SWISS ADME and shown in Table 1. Both the proposed drug molecules have 
molecular weight less than 875 gm/mol and topological polar surface area (TPSA) values less than 180 
Å2 (Table 1). All drug molecules have H-bond donors ≥6, H-bond acceptor ≥14 and have low synthetic 
 
accessibility count, this suggests that they can be synthesized easily. Though these drugs violate some 
drug likeness properties, still the availability of these drugs in the drug industry motivates us to consider 
these as potential inhibitors. Molecular docking study requires the ligand file in pdbqt format. AutoDock 
Tools 1.5.6 [52] have been used to save ligands in pdbqt format. 
2.3. Methods: Molecular docking and Molecular dynamics simulations 
To predict the target and drug interactions, molecular docking is commonly used in simulation. It 
minimizes the energy and calculates the binding energy of the interactions. In the molecular docking 
simulation, we normally make out the best pose of the ligand towards the receptor protein with the help 
of scoring functions [53]. Molecular docking can show the possibility of any biochemical reaction or 
whether a drug is docked with the receptor protein or not. The AutoDock vina with the best fitted 
parameters binding modes – 9, exhaustiveness – 8, applied maximum energy difference – 3 kcal/mol and 
Grid box center with x, y, and z coordinate of residue position of the protein is used for docking purpose 
[48]. AutoDock Tools [48] have been used for saving the target protein in pdbqt format. The criteria for 
choosing the best position from the docked 9 modes is the maximum nonbonded interaction, lower binding 
affinity (kcal/mol), dipole moment (Debye), dreiding energy and inhibition constant. Best ligand: protein 
pose is identified by knowing the types (H-bonds, hydrophobic bonds) and number of bonding between 
them. The drug which makes the maximum number of bonds with the target protein mostly shows better 
complex formation. For analyzing and visualizing non-bonded hydrogen bonds for different output poses, 
Discovery Studio visualizer 2020 version 20.1.0.19295 [49] have been used. After the analysis of 
individual docking, sequential docking is performed. For sequential docking, the grid box coordinates 
were set to the particular binding region of each drug with default grid spacing. In the procedure of 
sequential docking, the first ligand is docked and the complex is saved out as a single file, where the first 
ligand is considered part of the receptor. Docking is then carried out on this complex with the second 
ligand. The structural dynamics of receptor and inhibitor interaction and thermodynamics stability of 
ligand: protein have been investigated with the help of Linux based platform “GROMACS 5.1 Package'' 
[54], Different thermodynamic parameters like temperature (T), density (D), potential energy (Epot), root 
mean square deviation (RMSD) for backbone, root mean square fluctuation (RMSF) for protein Cα, 
solvent accessible surface area (SASA), intermolecular hydrogen bonds, interaction energies (∆G) of the 
protein and drug complex have been find out with CHARMM36 all atom [55] and GROMOS43A2 force 
fields [56]. In aqueous solution simulations have been performed using the water model: TIP3P. For 
 
solvation process protein in bare state, protein: ligand complex were solvated in a cubic box, with a buffer 
distance of 10 Å and volume as 893,000 A3. For electrically neutralizing the system four Na+ ions have 
been added. Then we minimize the energy in the vacuum. For energy minimization 50000 iterations have 
been taken. In the present work, we have observed that within 10 ps of the time scale all the complex 
formation reached stability so for the study we have restricted our simulation upto 10 ns. Number of 
particles (N), volume (V), and temperature (T) were constant under the 1 atmosphere pressure and 298K 
temperature. We have used Lennard-Jones and Coulomb short range interaction for the nonbonded 
interactions. Graphical tool Origin pro has been used to study the simulated results.  
“Molecular Mechanics Poisson-Boltzmann Surface Area” (MMPBSA) method [57] have been used for 
calculating the interaction free energies (ΔGbind) of the protein: drug complex. ΔGbind calculation usually 
begins after the MD simulation of the complex using the single trajectory approach. ΔGbind in the aqueous 
solvent, for the bound protein: ligand complex can be given as: 
∆𝐺𝑏𝑖𝑛𝑑,𝑎𝑞𝑢 = ∆𝐻 − 𝑇∆𝑆 ≈ ∆𝐸𝑀𝑀 + ∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣 − 𝑇∆𝑆 … … … … … . . (1) 
           ∆𝐸𝑀𝑀 = ∆𝐸𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡 + ∆𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 + ∆𝐸𝑣𝑎𝑛𝑑𝑒𝑟 𝑤𝑎𝑎𝑙𝑠 … . (2) 
∆𝐸𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡 = ∆𝐸𝑏𝑜𝑛𝑑 + ∆𝐸𝑎𝑛𝑔𝑙𝑒 + ∆𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛 … … … … … … (3) 
∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣 =  ∆𝐺𝑝𝑜𝑙𝑎𝑟 + ∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 … … … … … … … … … … (4) 
 
 
Where, ∆𝐸𝑀𝑀 is the molecular mechanical energy changes in gas phase and is the sum of 
covalent ∆𝐸𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡, electrostatic (∆𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐), and van der Waals energy (∆𝐸𝑣𝑎𝑛𝑑𝑒𝑟 𝑤𝑎𝑎𝑙𝑠 ) changes. 
Covalent energy is the combination of bond angle and torsion and ∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣 is separated into its polar 
and nonpolar contributions.∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣  is solvation free energy change and -TΔS conformational energy 
change due to binding.   
 
2.4. Computational facility 
 MD simulations and corresponding energy calculations have been computed using HP Intel Core    i5 - 




3. Results and discussion 
3.1. Individual docking of drugs against SARS-CoV-2 protease 
Ivermectin’s potential application for the treatment of various diseases in humans was confirmed 
a few years later. William C. Campbell and Satoshi Ōmura received the 2015 Nobel prize in physiology 
or medicine for the discovery and development of this drug [44,58,59]. Ivermectin has a broad-spectrum 
drug and possesses numerous effects on parasites, nematodes, arthropods, mycobacteria, flavivirus, and 
mammals [60]. By specifically targeting its NS3 helicase, it was also used to cure Japanese encephalitis 
virus (JEV) and yellow fever virus (YFV) [43,61]. Along this, it is also able to increase the immune 
system. Doxycycline is an antibiotic drug and used to treat the infections caused by bacteria. Doxycycline 
(C22H24N2O8) synthetically derived from oxytetracycline. This drug is a second-generation tetracycline, 
which is readily absorbed and bound to plasma proteins. It is mainly used for the treatment of 
pneumonia, respiratory tract infections, rocky mountain spotted fever, typhus fever, rickettsialpox, 
tick fevers, and urinary tract infections etc. It is also used to prevent malaria. Normally in the market it 
comes as a capsule, tablet, and suspension (liquid) to take orally. 
In the present work, ivermectin and doxycycline drugs were docked to SARS-CoV- 2 main 
protease (3CLpro) protein (6LU7). Ivermectin and doxycycline drugs confirm the Ro5 and other drug 
likeness rules etc. Hence, we have shown their strong application as potential drugs reaching the market 
(Table 1). 
Table 1. Molecular configuration and drug likeness properties of proposed ligand drug molecules for 
COVID-19 by SWISS ADME data. 
Pub Chem CID 6321424 54671203 
Name of Ligand Ivermectin Doxycycline 
Physiochemical Properties 
Molecular Formula  C48H74O14 C22H24N2O8 
Molecular Weight (g/mol) 875.09 g/mol 444.43 g/mol 
Hydrogen Bond Donor 
Count 
3 6 
Hydrogen Bond Acceptor 
Count 
14 9 
Rotatable Bond Count 8 2 
Topological Polar Surface 
Area 
170.06 Å² 181.62 Å² 
Heavy Atom Count 62 32 
Formal Charge 0.81 0.41 
Molar Refractivity 230.77 110.91 
 
Lipophilicity 
Log Po/w (iLOGP) 5.86 1.93 
Log Po/w (XLOGP3) 6.34 0.54 
Log Po/w (WLOGP) 5.60 -0.50 
Log Po/w (MLOGP) 1.25 -2.08 
Log Po/w (SILICOS-IT) 2.72 -0.98 
Consensus Log Po/w 4.35 -0.22 
Water Solubility 
Log S (SILICOS-IT) -8.73 -2.94 
class Poorly soluble Soluble 
Solubility 1.62e-06 mg/ml ; 1.85e-09 mol/l 5.07e-01 mg/ml ; 1.14e-03 mol/l 
Pharmacokinetics 
Gatrointestinal absorption Low Low 
BBB permanent No No 
P-gp substrate Yes Yes 
CYP1A2 inhibitor No No 
CP2C19 inhibitor No No 
Log Kp (skin permeation) -7.14 cm/s -8.63 cm/s 
Drug Likeness 
Lipinski Rule No; 2 violations: MW>500, NorO>10 Yes; 1 violation: NHorOH>5 
Ghose Filter No; 4 violations: MW>480, WLOGP>5.6, 
MR>130, #atoms>70 
No; 1 violation: WLOGP<-0.4 
Veber (GSK) Rule No; 1 violation: TPSA>140 No; 1 violation: TPSA>140 
Egan (phatmacial) Filter No; 1 violation: TPSA>131.6 No; 1 violation: TPSA>131.6 
Muegge (Bayer) Filter No; 4 violations: MW>600, XLOGP3>5, 
TPSA>150, H-acc>10 





PAINS (Pan Assey 
Interference Structures) 
0 alert  
                     0 alert 
 
Brenk 1 alert: isolated_alkene 1 alert: michael_acceptor_4 
Leadlikeness No; 3 violations: MW>350, Rotors>7, 
XLOGP3>3.5 
No; 1 violation: MW>350 




For the first experienced inhibitor ivermectin is docked with 3CLpro, 6LU7 protein. Based on 
molecular docking ivermectin: 6LU7 complex revealed 9 different poses. For finding out the best pose for 
the ligand and receptor complex formation, molecular docking simulation follows certain rules. The pose 
with highest negative values of binding energy, a greater number of hydrogen bonds and lowest value of 
dreiding energy and dipole moment considered as the best one. For ivermectin: 6LU7 complex, we have 
observed pose 3 is the better interacted position for ligand: protein complex with the binding affinity of -
6.9 kcal/mol. We have also computed the dreiding energy of different poses, in order to confirm the most 
excellent docked site. The dreiding energy (6,298.99) becomes minimum for the best docked 3 pose (Table 
2). 
To confirm the better interaction between ivermectin and 6LU7, we have calculated the inhibition 
constant (ki). It normally indicates how potent drugs inhibitors are towards protein. The inhibition constant 
can be calculated using the following equation: 
𝑘𝑖 = 𝑒
∆𝐺
𝑅𝑇    ………………………………(5) 
where G is binding affinity, R is universal constant and T is the room temperature (298 K). 
For the best docked 3 pose of ivermectin: 6LU7 complex, the obtained value of ki as 8.7 X 10-6M which 
proves the strong attraction of ivermectin towards protein 6LU7 (Table 2). The strong interaction for best 
docked pose (3) was further confirmed by the number of weak non-bonded hydrogen bonded interactions 
and hydrophobic interactions present between protein: ligand complex structure. “Hydrogen bonding and 
hydrophobic interactions” always stabilize the ligands at the target protein site [62]. We have observed 
the presence of intermolecular hydrogen bonds and hydrophobic interaction between protein and ligand. 
For best poses of ivermectin: protein complex, the donor–acceptor surface and different possible 
interactions in 3D and 2D view are shown in Figure 3 a. 
Same molecular docking approach has been done for doxycycline ligand with protein 6LU7. In 
terms of their different parameters (binding affinity value, dreiding energy, dipole moment, inhibition 
constants, number of hydrogen bonds, hydrophobic bonds etc.), we have identified the best possible 
ligand: protein docked pose position (Table 2). For doxycycline: protein complex, pose 7 is the better 
interacted position with the binding affinity of -6.4 kcal/mol, dreiding energy; 6,063.5, dipole moment; 
6.104 Debye, inhibition constant; 2.0 X 10-5 M and 7 number of hydrogen bonds (Table 2). Best pose of 
the donor–acceptor surface with their possible hydrogen bonding and hydrophobic interactions 3D and 
 
2D view are shown in Figure 3b. Our result shows that out of two possible ligand drug structures, 
ivermectin represents the best potentiality to inhibit with the SARS 3CLpro (6LU7) by its best docking 
affinity compared to the doxycycline. Good binding mode of interactions of ivermectin: 6LU7 complex 
also verified by its less binding energy, minimum inhibition constant value as compared to doxycycline. 
Both the drug molecules showed good stability as a complex with the targeted protein. These drug 
molecules also satisfy the required drug likeness properties according to Ro5, Veber etc. rules, polar 
surface areas and logP values. 








Hydrogen bonded interaction (donor: acceptor, distance in A) 













6LU7 -6.9 (A:THR25:HG1-:UNL1:O, 2.87667) [Conventional Hydrogen Bond] 
(A:THR26:HN-:UNL1:O, 2.03169) [Conventional Hydrogen Bond] 
(A:ASN142:HD22-:UNL1:O,2.79324)[Conventional Hydrogen Bond] 
(:UNL1:H-A:THR26:O, 2.45352) [Conventional Hydrogen Bond] 
(:UNL1:H-A:THR26:O, 2.13735) [Conventional Hydrogen Bond] 
(A:THR25:CA-UNL1:O, 3.40238) [Carbon atom Hydrogen Bond] 
(A:PRO168:CA-UNL1:O, 3.78628) [Carbon atom Hydrogen Bond] 
5.830 
 
6,298.99 8.7 X 10-6 
docking (Doxycycline) 
6LU7 -6.4 (A:ASN142:HD22-:UNL1:O, 3.03586)[Conventional Hydrogen Bond] 
(:UNL1:H-A:GLU166:O, 2.0088) [Conventional Hydrogen Bond] 
(:UNL1:H-A:GLN189:OE1, 2.12427) [Conventional Hydrogen Bond] 
(:UNL1:H-A:ASN142:OD1, 2.23539) [Conventional Hydrogen Bond] 
(:UNL1:H-:UNL1:O, 2.78645) [Conventional Hydrogen Bond] 
(:UNL1:H-:UNL1:O, 2.48006) [Conventional Hydrogen Bond] 
(:UNL1:C-A:HIS163:NE2, 3.59178) [Carbon atom Hydrogen Bond] 
6.104 
 
6,063.5 2.0 X 10-5 
Sequential docking (Ivermectin+Doxycycline) 
6LU7 -7.4 (A:GLY143:HN-:UNL1:O, 2.122)  [Conventional Hydrogen Bond] 
(A:GLY143:HN-:UNL1:O, 2.86002) [Conventional Hydrogen Bond] 
(A:SER144:HN-:UNL1:O2.32648)  [Conventional Hydrogen Bond] 
(A:SER144:HG-:UNL1:O2.1576) [Conventional Hydrogen Bond] 
(A:CYS145:HN-:UNL1:O,2.57732) [Conventional Hydrogen Bond] 
(A:GLU166:HN-:UNL1:O, 2.23187) [Conventional Hydrogen Bond] 
(UNL1:H- A:LEU141:O , 2.4969) [Conventional Hydrogen Bond] 
(:UNL1:H-:UNL1:O, 1.95212) [Conventional Hydrogen Bond] 
(:UNL1:C-A:ASN142:OD1, 3.4013) [Conventional Hydrogen Bond] 
(:UNL1:C-A:HIS41:NE2, 3.42481) [Conventional Hydrogen Bond] 
(:UNL1:C-A:GLN189:OE1, 3.5951) [Carbon atom Hydrogen Bond] 
2.237 
 
6,408.28 3.7 X 10-6 
 
 
Figure 3. Donor: acceptor surface and possible types of interactions in best pose structures obtained from 
molecular docking for a) ivermectin: 6LU7 b) doxycycline: 6LU7 complex. 
 
2-Dimensional view of ligand: Protein 
(Green colour; conventional H-Bonds, 
Sky blue: carbon H-Bonds, Pink; Alkyl) 
3-Dimensional view of ligand: Protein 
(Dark pink colour: H-Bonds donor 
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3.2. Sequential docking of two drugs against SARS-CoV-2 protease 
Individually, ivermectin and doxycycline drugs showed a good binding energy of -6.9 kcal/mol 
and -6.4 kcal/mol, respectively. The docked ligand molecules with the protease 3CLpro (6LU7) are shown 
in Figure 4a,b. The possible hydrophobic interactions and hydrogen bond between 6LU7of the two 
considered drugs obtained with individual docking are presented in Table 1. We have performed 
sequential docking for checking the interaction of combinational drugs (two or more than two drugs mixed 
to form a single drug) and the target protein. In the usual docking procedure we docked a single ligand 
with the receptor protein. However, with the help of sequential docking it is possible to dock more than 
two ligands simultaneously. This is helpful for detecting allosteric (place on protein where ligand that is 
not a substrate may bind) binding site. In the present work we have also checked the interaction of a 
combination of drugs (ivermectin+doxycycline) with the 6LU7 protein. Sequential docking of two drugs 
simultaneously with the 6LU7 protein showed a significant enhancement in the binding energy to -7.4 
kcal/mol (Figure 4 c). In Figure 4, the red circle indicates the binding drug site with their binding energies 
respectively. The two most suitable nearest poses which validate the best pose 1 structure for 
ivermectin+doxycycline: 6LU7 complex is shown in supporting document 1 (SD1).  Since sequential 
docking of ivermectin and doxycycline drugs with 6LU7 shows the better possibility of inhibition we have 
further studied the applicability of combination of these drugs as a potential drug by using MD simulation 
approach. 
 
Figure 4. Binding energies of (A) ivermectin: 6LU7 (B) doxycycline: 6LU7 (C) ivermectin+doxycycline: 




The stability of the particular complex is directly proportional to the number of nonbonded 
interactions. Larger the number of nonbonded interactions the more possibility of formation of complex 
structure. Maximum number of conventional hydrogen bonds and carbon hydrogen bonds (weak 
interactions) were observed for pose 1 of docked structure between ivermectin+doxycycline: 6LU7 
complex (Figure 3).   
 
3.3. MD simulation analysis 
MD simulation can simulate in picoseconds/nanoseconds or further finer temporal stead-fastness 
[63]. The MD simulation force field plays an important role for estimating the forces within the molecule 
(intramolecular force) and between two molecules (intermolecular force). These intermolecular and 
intramolecular forces used to calculate the potential energy of the molecules. The total energy of the 
system is given as the sum of bonded and non-bonded energy and given as below:  
𝐸𝑡𝑜𝑡𝑎𝑙 = 𝐸𝑏𝑜𝑛𝑑𝑒𝑑 + 𝐸𝑛𝑜𝑛 𝑏𝑜𝑛𝑑𝑒𝑑 … … … … … … … … … … … . (6) 
𝐸𝑏𝑜𝑛𝑑𝑒𝑑 = 𝐸𝑏𝑜𝑛𝑑 + 𝐸𝑎𝑛𝑔𝑙𝑒 + 𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 … … … … … … … … … … . . (7) 
𝐸𝑛𝑜𝑛 𝑏𝑜𝑛𝑑𝑒𝑑 = 𝐸ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛 𝑏𝑜𝑛𝑑 + 𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 + 𝐸𝑣𝑎𝑛𝑑𝑒𝑟 𝑤𝑎𝑎𝑙𝑠 … … … (8) 
𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 = 𝐸𝑐𝑜𝑢𝑙𝑜𝑚𝑏𝑖𝑐 + 𝐸𝑙𝑒𝑛𝑎𝑟𝑑 𝐽𝑜𝑛𝑒𝑠 … … … … … … … … . . (9) 
These equations show that the bonded energy is the combination of bond, angle and dihedral energies 
while nonbonded energy is the combination of hydrogen bond, electrostatic and van der waals energies 
(eq. 7, 8). 
To analyze the stability of the studied structure, MD simulation of the complexes (ivermectin: 6LU7, 
doxycycline: 6LU7, ivermectin+doxycycline: 6LU7) have been studied for the period of 10000 ps to 100 
ps. For MD simulation, first we have to make all the structure energetically optimized (the potential energy 
should be minimum and negative with a maximum force value). Figure 5 represents energetically 
minimized protein and complex systems. We have obtained steady convergence of potential energy for 
all the cases. The comparison of the potential energy (Epot) of the stable structure of bare 6LU7 protein 
and in drugs: 6LU7 complex has been done carefully. In the bare state 6LU7 has Epot of –1.27x106±56.7 
kJ/mol, while the complex ivermectin: 6LU7, doxycycline: 6LU7 and ivermectin+doxycycline: 6LU7 has 
 
an average Epot of –2.55661X105±11kJ/mol, –2.54672X105±14 kJ/mol, –2.48721X105 ±53 kJ/mol 
respectively (Table 3). Now all the structures having their lowest Epot values are ready for MD simulation. 
Figure 5: Potential energy surface for optimized geometry of bare 6LU7, ivermectin: 6LU7 complex, 
doxycycline: 6LU7 complex and ivermectin+doxycycline: 6LU7 complex. 
 
Figure 6: Temperature progression data for bare 6LU7, ivermectin: 6LU7, doxycycline: 6LU7 and 
ivermectin+doxycycline: 6LU7 complex in water environment in GROMOS and Charm 36 force fields. 
 
 
To stabilized different parameters (temperature (T), pressure (P), density (D), volume (V) etc.) within a 
time scale of 100 ps to 10000 ps, we have further check the optimized drugs: 6LU7 protein structures 
equilibrated by NVT and NPT ensembles. It is observed that over the period of 100 ps time trajectory the 
temperature of the  complex rapidly reached the stable at 300 K (room temperature) value (Figure 6). This 
temperature stability is maintained throughout the process. The temperature, pressure and density values 
of the system were also observed to be very stable over the period of time trajectory 100 ps (SD2, SD3). 
This concludes that the system is well equilibrated and prepared for MD simulation. 
The compactness of the system with respect to time of a bare protein and protein: ligand complex 
can be measured with the help of radius of gyration (Rg) [64]. Normally for the stably folded protein 
structures the values of Rg keeps a relatively steady for full time scale [65]. Whereas the Rg values for the 
unfolded protein keeps changing for full time scale. Less compactness in the structures and high 
compactness with more stability exhibit a low and high Rg value respectively. In the present paper we 
have observed the bare protein (6LU7) has Rg in between 2.25 nm – 2.26 nm with an average value of 
2.225 nm (SD 4, Table 3). Almost similar variation is observed with the proposed dugs: 6LU7 complex 
(SD 4). This shows high compactness with more stability in the protein and drugs complexes (SD 4). 
Further to validate the applicability of ivermectin, doxycycline and ivermectin+doxycycline 
ligands as proposed drug for COVID-19, we have simulated the SASA. SASA measures the area of 
exposure of the receptor to the solvents. The higher value of SASA indicates that the drug is more inserted 
into the water whereas, lower value represents that more drug is covered by the protein, which represents 
better complexation. In the present work, we have obtained the SASA value in the range of 19–26 nm2 for 
bare protein with the mean value 22 nm2 (SD 5, Table 3). Similarly, for all the proposed drug and protein 
6LU7 complex the mean value of SASA is 9 nm2. The low computed values of SASA observed for all 
drugs: protein complex shows that drug binding with the receptor protein increases the exposure of 








Figure 7: Hydrogen bond number for optimized geometry of a) ivermectin: 6LU7 complex, b) 
doxycycline: 6LU7 complex, and c) ivermectin+doxycycline: 6LU7 complex. 
 
Intermolecular hydrogen bonding plays a significant role to get an idea about the binding strength between 
protein and drug. Ivermectin has a stable range of intermolecular hydrogen bonding with protein between 
0 to 7 with an average value 3.5 in throughout the whole simulation process (Figure 7, Table 3).  
Doxycycline has a range of intermolecular hydrogen bonding with protein between 0 to 6 in throughout 
the whole simulation process with an average value of 3. However, the combination of both the drugs 
(ivermectin+doxycycline) has the highest stable range of intermolecular hydrogen bonding with protein 
between 0 to 12 with an average value 7 (Table 3). The intermolecular hydrogen bond number computed 
through MD simulation also perfectly matches with the docking results. This result clearly indicates that 
there is no conformational change around the probe drug systems in the binding site throughout the 
simulation process (Figure 7). The appearance of larger intermolecular hydrogen bonding in combination 
phase of ivermectin+doxycycline with the target protein 6LU7 validates best binding phase compared to 
single phase binding with receptor protein. 
 
Figure 8. Root mean square deviation (RMSD) of receptor protein 6LU7 in its bare state, ivermectin: 
6LU7 complex, doxycycline: 6LU7 and ivermectin+doxycycline: 6LU7 complex a) 3D view and b) 2D 




RMSD corresponds to any change in the conformational stability of the protein: drug complex and in the 
protein dynamics. RMSD of the free protein and protein: ligand complex have been simulated to 100 ns 
by using MD simulations. RMSD and RMSF have been measured by using the GROMACS module at an 
interval of 1 ns. RMSD variation of bare 6LU7 protein lies in the range from 0.08 to 0.16Å. Ivermectin: 
6LU7, doxycycline: 6LU7, ivermectin+doxycycline: 6LU7 complex, also ranges RMSD values from 0.08 
to 0.16 Å (Table 3). The RMSD value for complexes exactly matches with the bare protein. This provided 
a suitable basis for our study by the better stability with the probe drugs. Figure 8 represents the 2D and 
3D view of RMSD values of Cα atoms of the bare protein and protein: ligand complex individually at 
various nanoseconds. The RMSD graph of all three ligands showed stability during the simulations (Figure 
 
8). We have observed all the complexes are stable and no deviations of RMSD values were found 
throughout the simulations.  
Figure 9. Graph of root mean square fluctuations (RMSF) of 6LU7 in its bare state and in 
ivermectin+doxycycline: 6LU7 complex. 
 
 
For all amino acid residues with respect to Cα atom RMSF have been simulated. RMSF plot for 6LU7 in 
its bare state and ivermectin+doxycycline: 6LU7 complex have been shown in Figure 9, which depicts the 
fluctuations at the residue level.  Residue fluctuation profile for both the cases shows a similar trend having 
an average RMSF value of  0.15 Å, which  indicates that binding of both the drugs to the 6LU7 protein 






Table 3. MD simulation output parameters of 6LU7 in its bare state without any ligand and in the 




Parameter Bare 6LU7 Ivermectin:  6LU7 
complex 
Doxycycline: 6LU7 complex Ivermectin+Doxycycline: 
6LU7 complex 
Mean Range Mean Range Mean Range Mean Range 
1. SR Coulombic 
Interaction Energy (kJ 
/mol) 






-74--106 -84.9295 ±13   -90--40 
2. SR Lennard-Jones 
Interaction Energy (kJ/ 
mol) 




-87-113 -125.189±3.1 -135--111 
3. RMSD (nm) 0.12  0.08–0.16 0.12  0.08–
0.16 
0.12  0.08–0.16 0.12  0.08–0.16 
4. Inter H-Bonds NA NA 3.5 0-7 3 0-6  7 0-12 
5. Radius of gyration 2.25 ± 0.01  2.25–2.26 2.91 2.91-
2.93 
2.25  2.25–2.26 2.91 2.91-2.93 
6. SASA (nm2) 22 19–26 9 4-14 9 4-14 9 4-14 
























NA NA -8.718    ± 
25.676 
NA -6.677   ± 
41.724 
NA -10.603  ± 
41.086  
NA 
9. Van der Waal 
Energy(∆Evdw) (KJ/mol) 
NA NA -0.065   
±0.088 
NA -23.492   
± 49.768 





NA NA -0.324   
±0.704 
NA -8.506   
±19.752 
NA -0.483   ± 
3.815  
NA 
11. Polar Solvation 
Energy((∆Epolar)(KJ/mol) 
NA NA -8.527   
±25.583 
NA 27.758  ± 
43.697 
NA -9.737  
±41.527  
NA 
12. SASA Energy 
(∆Eapolar)(KJ/mol) 
NA NA 0.197   
±2.426 
NA -2.437  ± 
5.567 





The short-range nonbonded interaction energy (Coulombic short range protein: ligand interaction energy 
terms and Lennard Jones short range protein: ligand interaction energy terms) quantify the strength of the 
interaction between probe drugs and protein. Addition of Coulombic interaction energy and Lennard Jones 
interaction energy provides the total interaction energy. Figure 10 a,b shows the contour map and 3D 
graph of obtained total interaction energy for the ivermectin+doxycycline: 6LU7 complex. The average 
Coulombic interaction energy for ivermectin+doxycycline: 6LU7 complex comes out –84.9295±13 kJ/ 
mol whereas the average Lennard-Jones interaction energy is –125.189±3.1 kJ/mol (Table 3). Table 3 
represents all the Coulombic interaction energy and Lennard Jones interaction energy for individual drugs: 
protein complex and combination of drugs: protein complex. The comparison suggests that for all the 
 
complex formation, short-range Lennard-Jones has shown stronger effect on binding affinity than the short 
range Coulombic interaction energy.  
 
Figure 10: For ivermectin+doxycycline: 6LU7 complex a) contour plot of coulombic interaction energy 
and Lenard Jones interaction energy b) 3D representation of coulombic interaction energy and Lenard 
Jones interaction energy with respect to the time trajectory (0 to 10000 ps).
 
 
For the complex formation ΔG indicates the non-bonded interaction energies which is the sum of 
comprehensive energies of individual components while the binding energy through molecular docking 
provides only binding energy of the complex formation. Based on different quantum simulation 
techniques, there are a number of research works going on to check the stability of  varieties of complex 
configurations based on interaction energies [66,67] . Figure 11 represents the ΔG values for ivermectin: 
6LU7, doxycycline: 6LU7 and ivermectin+doxycycline: 6LU7 complex with respect to the time trajectory 
0 ps to 10000 ps. The observed ΔG values for ivermectin+doxycycline: 6LU7 complex is the lowest (–
10.603 ± 41.086 kJ/mol) in comparison of other complexes (ΔG for ivermectin –8.718±25.676, ΔG for 
doxycycline –8.718±25.676)(Table 3). This clearly indicates that ivermectin and doxycycline makes 
better complexation with the SARS-CoV-2 protein but the combination of these two drugs can make 
impressively best stable complex formation with receptor protein 6LU7.  
 
 
Figure 11: Total binding energy with respect to the time trajectory (0 to 10000 ps) for ivermectin: 6LU7 
complex, doxycycline: 6LU7 complex and ivermectin+doxycycline: 6LU7 complex.  
4. Conclusions
In conclusion, two drugs (ivermectin and doxycycline) were tested as potential inhibitors for 
COVID-19 main protease 6LU7 via molecular docking. A strong inhibitory possibility of proposed drugs 
for SARS-CoV-2 protease 3CLpro was verified by physiochemical, pharmacokinetics, drug likeness, and 
medicinal chemistry properties by using ADME analysis. From docked compounds, we have proposed 
that ivermectin and doxycycline demonstrated high binding affinity to the 6LU7 and their combined 
docking increases the binding affinity on COVID-19 main protease. Strong binding affinity, lowest 
inhibition constant and existence of hydrogen bonded interaction established the better stability of 
ivermectin+doxycycline: 6LU7 complex structure. Further studies also conducted on these compounds 
using MD simulations in order to get more reliable data. Many thermodynamic parameters (Epot, T, V, D, 
Rg, SASA energy) obtained by MD simulation also validated the complexation between 
ivermectin+doxycycline and 6LU7. The backbone of the complex and free 6LU7 protein illustrate similar 
RMSD and RMSF, which demonstrate the stability of the binding of drugs and protein. MD analyses have 
also confirmed the complexation between proposed drug and 6LU7 protein by the lower values of binding 
energy. All simulated results establish that combination of drugs is a stronger candidate as a potential 
 
inhibitor for SARS-CoV-2 than considering each drug separately. Our present in silico study would 
provide a new approach to the researchers working in the field of new drug finding against SARS-CoV-
2. However, a proper in-vivo and in-vitro rigorous research works are to be performed for the validation 
of our simulation work so that our recommended combination drug may be considered as a promising 
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